Filing Details
- Accession Number:
- 0000896262-21-000006
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2021-01-20 16:01:07
- Reporting Period:
- 2021-01-15
- Accepted Time:
- 2021-01-20 16:01:07
- SEC Url:
- Form 4 Filing
Issuer
Cik | Name | Symbol | Sector (SIC) | IRS No |
---|---|---|---|---|
896262 | Amedisys Inc | AMED | Services-Home Health Care Services (8082) | 113131700 |
Insiders
Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
---|---|---|---|---|---|---|---|
1694097 | Christopher Gerard | 3854 American Way, Suite A Baton Rouge LA 70816 | Chief Operating Officer | No | Yes | No | No |
Reported Non-Derivative Transactions
Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|---|---|---|---|---|---|
Common Stock | Disposition | 2021-01-15 | 31 | $287.13 | 27,639 | No | 4 | S | Direct | |
Common Stock | Disposition | 2021-01-15 | 225 | $288.33 | 27,414 | No | 4 | S | Direct | |
Common Stock | Disposition | 2021-01-15 | 113 | $289.45 | 27,301 | No | 4 | S | Direct | |
Common Stock | Disposition | 2021-01-15 | 105 | $290.59 | 27,196 | No | 4 | S | Direct | |
Common Stock | Disposition | 2021-01-15 | 122 | $291.43 | 27,074 | No | 4 | S | Direct | |
Common Stock | Disposition | 2021-01-15 | 95 | $292.49 | 26,979 | No | 4 | S | Direct | |
Common Stock | Disposition | 2021-01-15 | 59 | $293.45 | 26,920 | No | 4 | S | Direct |
Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|
No | 4 | S | Direct | |
No | 4 | S | Direct | |
No | 4 | S | Direct | |
No | 4 | S | Direct | |
No | 4 | S | Direct | |
No | 4 | S | Direct | |
No | 4 | S | Direct |
Reported Non-Derivative Holdings
Sec. Name | Remaning Holdings | Nature of Ownership | Explanation |
---|---|---|---|
Common Stock | 279 | Indirect | Through 401(k) Plan |
Footnotes
- These sales were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the reporting person.
- The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $286.91 to $287.43, inclusive. The reporting person undertakes to provide to Amedisys, Inc. (the "Issuer"), any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) to this Form 4.
- The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $287.94 to $288.90, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (3) to this Form 4.
- The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $289.01 to $290.00, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (4) to this Form 4.
- The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $290.04 to $291.00, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (5) to this Form 4.
- The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $291.05 to $291.99, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (6) to this Form 4.
- The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $292.11 to $292.99, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (7) to this Form 4.
- The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $293.34 to $293.745, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (8) to this Form 4.
- The information in this report is based on a plan statement dated as of December 31, 2020.